FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely endocrinology, and aims at diagnosing central hypogonadism in females. That is ensured by determining a basal level of luteinizing hormone, conducting a subcutaneous introduction of Diphereline 0.1 mg and evaluating the absolute luteinizing hormone content 4 hours after administering Diphereline. If observing baseline level of luteinizing hormone less than 1.95 IU/l and absolute luteinizing hormone content after sample less than 35 IU/l, central hypogonadism is diagnosed.
EFFECT: invention provides more accurate diagnosis of central hypogonadism in females.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC METHOD OF CENTRAL HYPOGONADISM IN FEMALES | 2019 |
|
RU2710539C1 |
| METHOD FOR DIAGNOSING ORGANIC LESIONS OF THE CHIASMAL-SELLAR REGION IN PATIENTS WITH CENTRAL HYPOGONADISM | 2021 |
|
RU2777475C1 |
| METHOD FOR DETERMINING THE AGING STAGE OF THE REPRODUCTIVE SYSTEM IN CENTRAL FEMALE HYPOGONADISM | 2019 |
|
RU2714681C1 |
| METHOD FOR PREDICTING HOLLOW FOLLICLES SYNDROME | 2005 |
|
RU2302639C1 |
| METHOD FOR DESCRIBING NATURE OF ARRESTED SEXUAL DEVELOPMENT IN BOYS IN PUBERTY WITH GROWTH RETARDATION | 2011 |
|
RU2462720C1 |
| METHOD FOR DIAGNOSING THE TYPE OF NORMOGONADOTROPIC OVULATORY DYSFUNCTION IN PATIENTS WITH MENSTRUAL DISORDERS | 2021 |
|
RU2765114C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF PITUITARY INCIDENTALOMA | 2023 |
|
RU2822656C1 |
| METHOD FOR AROMATASE ACTIVITY TEST | 2012 |
|
RU2481587C1 |
| METHOD FOR TREATMENT OF ADOLESCENT HYPOGONADOTROPIC HYPOGONADISM IN EXPERIMENT | 2020 |
|
RU2750713C1 |
| METHOD OF DIAGNOSIS OF FOLLITROPIN AND LUTROPIN HYPERSECRETION | 2000 |
|
RU2177620C2 |
